OncoPATH - the ColoNET Follow-up: Dissecting and modelling vulnerabilities of oncogenic pathways and metabolism in solid cancers

The overall aim of the OncoPATH Consortium is to analyze the qualitative and quantitative impact of frequent genetic and epigenetic alterations on the signaling pathways and metabolic networks in colorectal cancer cells. The changes in the metabolic networks and in signal transduction will be integrated into a mathematical model and functionally analyzed. Thereby, the theoretical model will be successively adapted and improved resembling single experimental models (e.g. a cell line) or even individual patients. The model can then be used to simulate therapeutic interference and propose new therapeutic options.

More information about Opens external link in current windowOncoPATH

 

 

Partners

Christine Sers, Charité – Universitätsmedizin, Coordiator OncoPATH
Nils Blüthgen, Charité – Universitätsmedizin, Coordinator OncoPATH
Reinhold Schäfer, Charité – Universitätsmedizin

Markus Morkel, Charité – Universitätsmedizin
Ulf Leser, Humboldt Universität zu Berlin
Edda Klipp, Humboldt Universität zu Berlin
Tilmann Brummer, Institute of Molecular Medicine and Cell Research, University of Freiburg
Stefan Legewie, Institute of Molecular Biology, Mainz
Stefan Kempa, Max Delbrück Center for Molecular Medicine
Iduna Fichtner, EPO GmbH, Berlin

 

 

Supported by:

BMBF, e:BIO, 01/2013- 12/2015

 

 

 

Group leader

Prof. Dr. rer. nat. Christine Sers
Head of group Mol. Tumor Pathology, Head of group Tumor Systems Biology
t: +49 30 450 536 185